
Opinion|Videos|May 2, 2025
Understanding OS Through 2 Lenses: Patients and Providers in EGFRm NSCLC
Panelists discuss how health care providers and patients view survival differently, with providers being more data driven and patients focusing on living with minimal symptoms and maintaining quality of life.
Advertisement
Episodes in this series

Patient vs Health Care Provider Perspectives on Treatment Goals
Main Discussion Topics:
- Differences between how patients and providers view survival benefits
- Patient priorities regarding quality of life and symptom management
- Challenges in communicating complex efficacy data to newly diagnosed patients
Key Points for Physicians:
- Health care providers tend to be more data driven in their approach
- Patients often prioritize living with minimal symptoms and maintaining normalcy
- Newly diagnosed patients may be overwhelmed and unable to process statistical benefits
Notable Insights:
There is an emotional component to treatment decision-making that physicians must navigate, particularly when patients are still processing their diagnosis.
Clinical Significance:
Effective communication with patients requires understanding their priorities and emotional state, moving beyond statistical data to address their specific concerns and goals.
Advertisement
Related to this article

The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.

Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.

Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.

A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.

The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
4
Dr Viansone on De-Escalating Chemotherapy Type and Duration in HER2-Positive Breast Cancer
5

